USANA Health Sciences (NYSE:USNA) Given New $35.00 Price Target at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price target cut by analysts at DA Davidson from $38.00 to $35.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. DA Davidson’s target price would suggest a potential downside of 7.43% from the stock’s previous close. DA Davidson also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, FY2024 earnings at $2.45 EPS and FY2025 earnings at $2.23 EPS.

Separately, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th.

USANA Health Sciences Stock Up 3.4 %

USNA opened at $37.81 on Wednesday. The stock has a market cap of $720.28 million, a price-to-earnings ratio of 13.36, a PEG ratio of 1.15 and a beta of 0.89. USANA Health Sciences has a twelve month low of $34.15 and a twelve month high of $54.81. The company’s 50-day moving average price is $37.96 and its two-hundred day moving average price is $42.51.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The firm had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same period in the previous year, the company earned $0.59 earnings per share. As a group, sell-side analysts anticipate that USANA Health Sciences will post 2.5 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently made changes to their positions in the stock. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 24.4% during the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock valued at $44,183,000 after buying an additional 191,289 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of USANA Health Sciences by 14.3% during the 2nd quarter. Pacer Advisors Inc. now owns 467,352 shares of the company’s stock valued at $21,143,000 after buying an additional 58,597 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in USANA Health Sciences by 14,068.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock worth $1,472,000 after purchasing an additional 38,547 shares during the period. Assenagon Asset Management S.A. raised its position in USANA Health Sciences by 32.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 109,252 shares of the company’s stock worth $4,943,000 after purchasing an additional 27,053 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its position in USANA Health Sciences by 297.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company’s stock worth $1,346,000 after purchasing an additional 22,251 shares during the period. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.